Today is shaping up negative for Cue Biopharma, Inc. (NASDAQ:CUE) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per ...

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively ...

CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to ...